title: Amyloid PET imaging in patients with mild cognitive impairment: a 2-year follow-up study.
abstract: BACKGROUND
  Patients with amnestic mild cognitive impairment (MCI) have greater risk of conversion to Alzheimer disease (AD). Increased brain amyloid burden in AD and MCI has been demonstrated with PET using [(11)C] Pittsburgh compound B (PiB) as a tracer.
  
  
  OBJECTIVE
  To evaluate change in β-amyloid deposition in with MCI during 2-year follow-up.
  
  
  METHODS
  Patients with MCI and controls were studied with [(11)C] PiB PET, MRI, and neuropsychometry at baseline and these investigations were repeated in patients with MCI after follow-up.
  
  
  RESULTS
  Those patients with MCI converting to AD during follow-up had greater [(11)C] PiB retention in the posterior cingulate (p=0.020), in the lateral frontal cortex (p=0.006), in the temporal cortex (p=0.022), in the putamen (p=0.041), and in the caudate nucleus (p=0.025) as compared to nonconverters. In converters, there was no significant change in [(11)C] PiB uptake, whereas an increase was seen as compared to baseline in nonconverters in the anterior and posterior cingulate, temporal and parietal cortices, and putamen. Hippocampal atrophy was greater in converters at baseline than in nonconverters, but increased significantly in both groups during follow-up.
  
  
  CONCLUSIONS
  Hippocampal atrophy and amyloid deposition seem to dissociate during the evolution of MCI, the atrophy increasing clearly and [(11)C] PiB retention changing modestly when conversion to AD occurs. Longer follow-up is needed to determine whether nonconverters would convert to AD later, which would suggest accelerated [(11)C] PiB retention preceding clinical conversion.
authors.affiliation: Turku PET Centre, University of Turku, Turku, Finland.
authors.forename: J
authors.initials: J
authors.lastname: Koivunen
authors.forename: N
authors.initials: N
authors.lastname: Scheinin
authors.forename: J R
authors.initials: JR
authors.lastname: Virta
authors.forename: S
authors.initials: S
authors.lastname: Aalto
authors.forename: T
authors.initials: T
authors.lastname: Vahlberg
authors.forename: K
authors.initials: K
authors.lastname: Någren
authors.forename: S
authors.initials: S
authors.lastname: Helin
authors.forename: R
authors.initials: R
authors.lastname: Parkkola
authors.forename: M
authors.initials: M
authors.lastname: Viitanen
authors.forename: J O
authors.initials: JO
authors.lastname: Rinne
mesh_terms: D000368:Aged; D000544:Alzheimer Disease / Q000150:complications / Q000000981:diagnostic imaging / Q000378:metabolism / Q000473:pathology; D016229:Amyloid beta-Peptides / Q000378:metabolism*; D000814:Aniline Compounds; D001284:Atrophy / Q000150:complications / Q000000981:diagnostic imaging; D001921:Brain / Q000000981:diagnostic imaging / Q000378:metabolism* / Q000473:pathology*; D002250:Carbon Radioisotopes; D003072:Cognition Disorders / Q000150:complications / Q000000981:diagnostic imaging / Q000378:metabolism* / Q000473:pathology*; D018450:Disease Progression; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D009483:Neuropsychological Tests; D049268:Positron-Emission Tomography / Q000379:methods*; D013844:Thiazoles
chemical_list: C475519:2-(4'-(methylamino)phenyl)-6-hydroxybenzothiazole; D016229:Amyloid beta-Peptides; D000814:Aniline Compounds; D002250:Carbon Radioisotopes; D013844:Thiazoles